Acute Myeloid Leukemia Therapeutics Market

Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years.
Acute Myeloid Leukemia Therapeutics Market aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia Therapeutics. Acute Myeloid Leukemia Therapeutics Market contains market size and forecasts of Acute Myeloid Leukemia Therapeutics in global, including the following market information:
Global Acute Myeloid Leukemia Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Acute Myeloid Leukemia Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Geographically, acute myeloid leukemia therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, North America held substantial share of the acute myeloid leukemia therapeutics market owing to prominent growth factors including rising incidences of acute myeloid leukemia and increasing geriatric population. Furthermore, advanced healthcare infrastructure, rising need of targeted therapies, huge investment in the development of pipeline drugs, and awareness amongst the population base induced market growth in this region. Asia Pacific is expected to be the fastest growing region over the forecast period owing to growth factors such as rising investments, rising disposable incomes, increasing cancer awareness, and improving healthcare infrastructure. Additionally, increasing inclination towards therapies such as targeted therapies resulting in low collateral damage and stronger efficacy is also anticipated to propel the demand for the acute myeloid leukemia therapeutics market in this region.
We surveyed the Acute Myeloid Leukemia Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Myeloid Leukemia Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Acute Myeloid Leukemia Therapeutics Market Segment Percentages, by Type, 2022 (%)
Pipeline Drugs
Chemotherapy Drugs
Chemotherapy Regimens
Global Acute Myeloid Leukemia Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Acute Myeloid Leukemia Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Home Care
Global Acute Myeloid Leukemia Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Acute Myeloid Leukemia Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Myeloid Leukemia Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Acute Myeloid Leukemia Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Ambit Biosciences Corporation
Genzyme Corporation Celgene Corporation
Clavis Pharma ASA
Sunesis Pharmaceuticals
Cephalon
Bristol-Myers Squibb
Novartis International AG
GlaxoSmithKline
Outline of Major Chapters:
Chapter 1: Introduces the definition of Acute Myeloid Leukemia Therapeutics, market overview.
Chapter 2: Global Acute Myeloid Leukemia Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Acute Myeloid Leukemia Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.